Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488392 | 0.75 | — | — | |
| SCHEMBL19408665 | 0.75 | — | — | |
| SCHEMBL11964810 | 0.75 | — | — | |
| SCHEMBL31672998 | 0.74 | GABRR1 (0.38) | — | |
| SCHEMBL3795520 | 0.73 | PPARG (0.36) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6037154 | 0.71 | PGK1 (0.45) | — | |
| SCHEMBL12227795 | 0.71 | CA1 (0.34) | — | |
| SCHEMBL15868134 | 0.71 | CA2 (0.42) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2289857 | 0.70 | PTGS1 (0.41) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4314030 | 0.70 | PTGS1 (0.41) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038404-A1 | MACROCYCLIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH | 2015-02-05 | — | — | US | disclosed |
| WO-2013130358-A1 | MACROCYCLIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-09-06 | — | — | WO | disclosed |
| US-6939565-B2 | Protease inhibitors of the coagulation cascade isolated from Dysidea sponges | PHARMACIA CORPORATION (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1465866-A4 | PROTEASE INHIBITORS OF THE COAGULATION CASCADE ISOLATED FROM DYSIDEA SPONGES | PHARMACIA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1465866-A2 | PROTEASE INHIBITORS OF THE COAGULATION CASCADE ISOLATED FROM DYSIDEA SPONGES | Pharmacia Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040147456-A1 | Protease inhibitors of the coagulation cascade isolated from Dysidea sponges | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | disclosed |
| US-6716869-B2 | N-(2-(1-AMIDINOPYRROL-3-YL)ETHYL)-5,6-DIHYDROXY-1-(2-(2-METHOX Y-3-SULFATOPROPIONYLAMINO)-3-CHLORO-4-METHYLVALEROYL)INDOLE-2-CARBOXAMIDE | PHARMACIA CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20030158248-A1 | Protease inhibitors of the coagulation cascade isolated from dysidea sponges | PHARMACIA CORPORATION | 2003-08-21 | — | — | US | disclosed |
| WO-2003051831-A2 | PROTEASE INHIBITORS OF THE COAGULATION CASCADE ISOLATED FROM DYSIDEA SPONGES | PHARMACIA CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147456-A1 | Protease inhibitors of the coagulation cascade isolated from Dysidea sponges | TFPI, TFPI2, HABP2 | SLC1A3 4846/4885SLC1A2 4870/4885SLC1A1 4847/4885 |
| US-20030158248-A1 | Protease inhibitors of the coagulation cascade isolated from dysidea sponges | TFPI, TFPI2, HABP2 | SLC1A3 4846/4885SLC1A2 4870/4885SLC1A1 4847/4885 |
| US-20150038404-A1 | MACROCYCLIC COMPOUNDS | SERPINB1, ELANE, CELA1 | SLC1A3 4431/4885SLC1A2 4709/4885SLC1A1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.